The object of the present invention is to provide a pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-κB. The pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-κB contains DTCM glutarimide of the Formula (I) as an effective ingredient, thereby being able to inhibit nitric oxide (NO)production and prostaglandin production.
-
Page/Page column 5-6
(2011/04/25)
Synthesis and antiviral activities of synthetic glutarimide derivatives
A series of novel glutarimide compounds were synthesized and their antiviral activities were evaluated. The compounds displaying the strongest antiviral activities included 5, 6f, 7e and 9 against coxsackievirus B3 (Cox B3), 10 and 6f against influenza vi
Ji, Xing-Yue,Zhong, Zhao-Jin,Xue, Si-Tu,Meng, Shuai,He, Wei-Ying,Gao, Rong-Mei,Li, Yu-Huan,Li, Zhuo-Rong
experimental part
p. 1436 - 1441
(2010/12/25)
Synthesis and biological evaluation on novel analogs of 9-methylstreptimidone, an inhibitor of NF-κB
Synthesis of 9-methylstreptimidone analogs and their inhibitory activities against NF-κB (nuclear factor-κB) are reported. Among several active derivatives synthesized in this study, 8 with a relatively simple structure, exhibited inhibitory activity agai
Synthesis and Biological Activity of 3-(6,7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolylmethyl)glutarimide
Condensation of 3-carboxymethylglutarimide (5) with 3,4-dimethoxyphenethylamine gives the required 3-(3,4-dimethoxyphenethylcarbamoylmethyl)glutarimide (6) along with N-β-(3,4-dimethoxyphenethyl)-3-(3,4-dimethoxyphenethylcarbamoylmethyl)glutarimide (7).Th
Gupta, K. A.,Saxena, Anil K.,Jain, Padam C.,Anand, Nitya
p. 341 - 343
(2007/10/02)
More Articles about upstream products of 6258-28-2